Member Exclusive News

The week in industry: NICE rejects KEYTRUDA® as treatment for head and neck cancer

This week: an advanced prostate cancer treatment granted US FDA priority review and a partnership announced that will leverage AI and computational biophysics to develop novel cancer therapies.

Go to the profile of RxNet
Jan 16, 2020
0
0

Please sign in or register for FREE

No comments yet.